Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
- PMID: 26858122
- PMCID: PMC5500167
- DOI: 10.1016/S1470-2045(15)00544-6
Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study
Abstract
Background: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We aimed to assess durvalumab plus tremelimumab in patients with advanced squamous or non-squamous non-small cell lung cancer (NSCLC).
Methods: We did a multicentre, non-randomised, open-label, phase 1b study at five cancer centres in the USA. We enrolled immunotherapy-naive patients aged 18 years or older with confirmed locally advanced or metastatic NSCLC. We gave patients durvalumab in doses of 3 mg/kg, 10 mg/kg, 15 mg/kg, or 20 mg/kg every 4 weeks, or 10 mg/kg every 2 weeks, and tremelimumab in doses of 1 mg/kg, 3 mg/kg, or 10 mg/kg every 4 weeks for six doses then every 12 weeks for three doses. The primary endpoint of the dose-escalation phase was safety. Safety analyses were based on the as-treated population. The dose-expansion phase of the study is ongoing. This study is registered with ClinicalTrials.gov, number NCT02000947.
Findings: Between Oct 28, 2013, and April 1, 2015, 102 patients were enrolled into the dose-escalation phase and received treatment. At the time of this analysis (June 1, 2015), median follow-up was 18·8 weeks (IQR 11-33). The maximum tolerated dose was exceeded in the cohort receiving durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg, with two (30%) of six patients having a dose-limiting toxicity (one grade 3 increased aspartate aminotransferase and alanine aminotransferase and one grade 4 increased lipase). The most frequent treatment-related grade 3 and 4 adverse events were diarrhoea (11 [11%]), colitis (nine [9%]), and increased lipase (eight [8%]). Discontinuations attributable to treatment-related adverse events occurred in 29 (28%) of 102 patients. Treatment-related serious adverse events occurred in 37 (36%) of 102 patients. 22 patients died during the study, and three deaths were related to treatment. The treatment-related deaths were due to complications arising from myasthenia gravis (durvalumab 10 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg), and neuromuscular disorder (durvalumab 20 mg/kg every 4 weeks plus tremelimumab 3 mg/kg). Evidence of clinical activity was noted both in patients with PD-L1-positive tumours and in those with PD-L1-negative tumours. Investigator-reported confirmed objective responses were achieved by six (23%, 95% CI 9-44) of 26 patients in the combined tremelimumab 1 mg/kg cohort, comprising two (22%, 95% CI 3-60) of nine patients with PD-L1-positive tumours and four (29%, 95% CI 8-58) of 14 patients with PD-L1-negative tumours, including those with no PD-L1 staining (four [40%, 95% CI 12-74] of ten patients).
Interpretation: Durvalumab 20 mg/kg every 4 weeks plus tremelimumab 1 mg/kg showed a manageable tolerability profile, with antitumour activity irrespective of PD-L1 status, and was selected as the dose for phase 3 studies, which are ongoing.
Funding: MedImmune.
Copyright © 2016 Elsevier Ltd. All rights reserved.
Conflict of interest statement
SA has served on Advisory Boards for MedImmune and AstraZeneca. SG has received research funding from AstraZeneca and Boehringer Ingelheim and has served on Advisory Boards for Clovis. AB has received financial support to run clinical trials from Genentech, Incyte, MedImmune, and Merck; and fees for Speaker Bureau participation from Bristol-Myers Squibb and Merck. JC has received financial clinical trial support from AstraZeneca/MedImmune and has received personal fees from Genentech. AG, KS, YG, JK, and RN are employees of MedImmune; JK, YG, AG, KS, and RN also own stock/stock options in AstraZeneca. YG was previously an employee of Boehringer Ingelheim. JK is also an employee of MedStar Montgomery Medical Center and Fauquier Hospital. KS has a provisional patent application related to this work. NR has received personal fees from AstraZeneca, BMS, Roche, Novartis, and Merck. SA has received an NIH grant. RS declares no competing interests.
Figures
Comment in
-
The race for combined checkpoint inhibition in NSCLC.Lancet Oncol. 2016 Mar;17(3):259-260. doi: 10.1016/S1470-2045(15)00580-X. Epub 2016 Feb 6. Lancet Oncol. 2016. PMID: 26858123 No abstract available.
Similar articles
-
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial.Lancet Oncol. 2022 Feb;23(2):279-291. doi: 10.1016/S1470-2045(21)00658-6. Epub 2022 Jan 13. Lancet Oncol. 2022. PMID: 35033226 Free PMC article. Clinical Trial.
-
Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.Lancet Oncol. 2020 Dec;21(12):1574-1588. doi: 10.1016/S1470-2045(20)30541-6. Epub 2020 Sep 21. Lancet Oncol. 2020. PMID: 32971005 Clinical Trial.
-
Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.Lancet Oncol. 2021 Jan;22(1):51-65. doi: 10.1016/S1470-2045(20)30539-8. Epub 2020 Dec 4. Lancet Oncol. 2021. PMID: 33285097 Clinical Trial.
-
Durvalumab for the treatment of non-small cell lung cancer.Expert Rev Anticancer Ther. 2019 Dec;19(12):1009-1016. doi: 10.1080/14737140.2019.1699407. Epub 2019 Dec 3. Expert Rev Anticancer Ther. 2019. PMID: 31782989 Review.
-
Durvalumab for the treatment of non-small cell lung cancer.Expert Rev Respir Med. 2018 Aug;12(8):627-639. doi: 10.1080/17476348.2018.1494575. Epub 2018 Jul 9. Expert Rev Respir Med. 2018. PMID: 29958099 Review.
Cited by
-
NRG1 Fusions in NSCLC: Being eNRGy Conscious.Lung Cancer (Auckl). 2024 Oct 3;15:143-148. doi: 10.2147/LCTT.S464626. eCollection 2024. Lung Cancer (Auckl). 2024. PMID: 39376790 Free PMC article. Review.
-
A phase 1 study of the CD40 agonist MEDI5083 in combination with durvalumab in patients with advanced solid tumors.Immunotherapy. 2024;16(11):759-774. doi: 10.1080/1750743X.2024.2359359. Epub 2024 Sep 12. Immunotherapy. 2024. PMID: 39264730 Free PMC article. Clinical Trial.
-
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer.J Hematol Oncol. 2024 Jul 27;17(1):54. doi: 10.1186/s13045-024-01581-2. J Hematol Oncol. 2024. PMID: 39068460 Free PMC article. Review.
-
Safety and clinical activity of durvalumab combined with tremelimumab in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase I study.ESMO Open. 2024 Aug;9(8):103646. doi: 10.1016/j.esmoop.2024.103646. Epub 2024 Jul 23. ESMO Open. 2024. PMID: 39043009 Free PMC article. Clinical Trial.
-
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small Cell Lung Cancer: The Phase II BALTIC Study.Clin Cancer Res. 2024 Sep 13;30(18):4055-4067. doi: 10.1158/1078-0432.CCR-24-0013. Clin Cancer Res. 2024. PMID: 39017667 Free PMC article. Clinical Trial.
References
-
- Kvistborg P, Philips D, Kelderman S, et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med. 2014;6:254ra128. - PubMed
-
- Rizvi NA, Gettinger SN, Goldman JW, et al. Safety and efficacy of first-line nivolumab (NIVO; anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC) J Thorac Oncol. 2015;10(9_Suppl.2):S176. (Oral02.05)
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous